NOV 14, 2019 10:30 AM PST

Identifying the PIK3CA mutations that make a difference in breast cancer with the QIAGEN therascreen® PIK3CA RGQ PCR Kit

Sponsored by: QIAGEN
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Global Product Manager, Oncology & Precision Diagnostics, QIAGEN
    Biography
      Ben is a member of the Oncology Diagnostics Global Product Management team at QIAGEN, with responsibility for commercialisation of innovative new Companion Diagnostic tests around the world, including the therascreen FGFR RGQ RT-PCR Kit recently approved by the FDA in the USA.

      A molecular biologist and immunologist by qualification, he has over a decade of experience in the IVD industry covering a range of roles including assay development, manufacturing and product management.

      He is based in Manchester, UK, the QIAGEN global centre of excellence for companion diagnostic development, where the FGFR RGQ RT-PCR Kit was originally developed.

    Abstract

    Breast cancer is the most frequently occurring form of cancer in women.  Whilst 5-year survival rates for localized disease approach 99%, cases of advanced breast cancer have a much poorer prognosis, with 5-year survival of around 27%.  Therefore, new treatment modalities for this indication are clearly welcome.  The Novartis drug PIQRAYTM (alpelisib) is the first -selective PI3Kinase inhibitor to be approved by the FDA for treatment of cases of advanced Hormone Receptor +ve / HER2 -ve breast cancer that also harbour activating mutations in the PIK3CA gene.  There are present in about 40% of cases, and therefore, it is necessary to use a companion diagnostic (CDx) test to identify patients eligible for treatment.  The therascreen PIK3CA RGQ PCR Kit is a rapid and reliable test, able to detect the presence of any of the 11 clinically actionable PIK3CA mutations in DNA from both FFPE tumor tissue and plasma specimens.  Clinically validated during the SOLAR-1 clinical trial, this test is currently the only FDA-approved CDx for this indication.  Available in the USA since May 2019, the Kit supports the delivery of precision medicine to patients for whom few other treatment options may remain.


    Show Resources
    NOV 14, 2019 10:30 AM PST

    Identifying the PIK3CA mutations that make a difference in breast cancer with the QIAGEN therascreen® PIK3CA RGQ PCR Kit

    Sponsored by: QIAGEN
    C.E. Credits: P.A.C.E. CE Florida CE

    Specialty

    Molecular Biology

    Cell Biology

    Immunology

    Pcr/rt-Pcr/real-Time Pcr

    Laboratory Testing

    Gene Expression

    Biotechnology

    Antibodies

    Molecular Diagnostics

    Biomarkers

    Clinical Research

    Microbiology

    Gene Sequencing

    Biochemistry

    Dna Sequencing

    Geography

    Asia57%

    North America43%

    Registration Source

    Website Visitors57%

    Email Promotions14%

    Trending Newsletter Promotion14%

    Other14%

    Job Title

    Student25%

    Educator/Faculty25%

    Medical Laboratory Technician25%

    Veterinarian25%

    Organization

    Academic Institution43%

    Veterinary School14%

    Medical School14%

    Consultant14%

    Research Institute14%


    Show Resources
    Show Resources
    Attendees
    • See more